New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 22, 2014
12:39 EDTISIS, BIIB, SNY, AVNR, BMYThese five companies will benefit from increased ALS awareness, MarketWatch says
A recent surge in funding for Lou Gehrig's disease, or ALS, caused by the Ice Bucket challenge that is widespread on social media outlets, will benefit five pharmaceutical companies that are involved in the development of a cure for ALS, according to MarketWatch. The companies that are or have been involved in developing a treatment for ALS include Biogen Idec (BIIB), Avanir Pharmaceuticals (AVNR), Isis Pharmaceuticals (ISIS), Sanofi (SNY), and Bristol-Myers Squibb (BMY), MarketWatch added. Reference Link
News For BMY;SNY;ISIS;AVNR;BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
April 20, 2015
09:20 EDTSNYLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
08:12 EDTBMYVanda names Tom Gibbs as SVP and Chief Commercial OfficerBristol-Myers
Subscribe for More Information
07:32 EDTBIIBBiogen says new data supports Tecfidera as long-term treatment for MS patients
Subscribe for More Information
07:20 EDTISIS, BMYAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information
07:18 EDTBIIB, AVNRAmerican Academy of Neurology to hold annual meeting
Subscribe for More Information
April 17, 2015
09:41 EDTBMYBristol-Myers up after Phase III Opdivo study met endpoint, trial stopped early
Subscribe for More Information
09:36 EDTBMYActive equity options trading on open
Subscribe for More Information
09:08 EDTBMYBristol-Myers data should be positive, says SunTrust
SunTrust expects the AACR data for Bristol-Myers' CheckMate-069 Opdivo + Yervoy combo, a treatment for melanoma, to show a positive overall response rate and progressive free survival that exceeds its prior -0004 results. The firm notes that the data is due to be presented on April 20. It raised its 2020 Opdivo revenue estimate to $7.1B versus the Street's $6.9B and raised its price target o n he stock to $74 from $70 while keeping a Buy rating on the shares.
08:58 EDTBMYBristol-Myers jumps 4% after Opdivo study stopped early after meeting endpoint
Subscribe for More Information
08:56 EDTBMYBristol-Myers says Phase III Opdivo study met endpoint, trial stopped early
Subscribe for More Information
April 16, 2015
12:16 EDTBMYEli Lilly and Bristol-Myers restructure Erbitux collaboration in N. America
Subscribe for More Information
08:59 EDTBMYGene therapy companies could benefit from increased attention, says Roth Capital
Subscribe for More Information
April 15, 2015
11:56 EDTSNYSanofi initiated with a Buy at Societe Generale
Subscribe for More Information
09:08 EDTBMYOn The Fly: Pre-market Movers
Subscribe for More Information
07:41 EDTSNY, BMYEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.
07:14 EDTBIIBBiogen volatility flat into new drug data
Biogen overall option implied volatility of 35 compares to its 26-week average of 34 according to Track Data, suggesting non-directional into results as shares rally in the preopen on Phase 2 RENEW study of anti-LINGO-1 in acute optic neuritis clinical data.
07:03 EDTBMYLexicon and Bristol-Myers select development candidate for neuropathic pain
Subscribe for More Information
April 14, 2015
18:30 EDTBIIBOn The Fly: After Hours Movers
Subscribe for More Information
16:12 EDTBIIBBiogen presents new Anti-LINGO-1 Phase 2 AON data
Subscribe for More Information
11:25 EDTBIIBPTAB declares interference between Forward Pharma and Biogen regarding treatment
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use